Dr John Nieland | Chief Operating Officer
2A Pharma

Dr John Nieland, Chief Operating Officer, 2A Pharma

Dr Nieland has an extensive research background in immunology and expertise in the development of biopharmaceuticals and coordination and development of clinical trials. He worked as Head of Immunology and later Director of Research at Medigene AG, where was involved in the development of the AAVLP-HPV vaccine, and held the position of Vice President Preclinical Research at Borean Pharma. John has initiated and collaborated on numerous projects, has published more than 30 articles and is the inventor of 15 patents, including several on the AAVLP vaccine platform. In addition to his scientific experience, John has extensive business experience and is the founder/co-founder of three biotech companies.



DC Co-conference Day 2 April 4 @ 3:55

The AAVLP platform for prophylactic and therapeutic vaccines with special focus on HPV-L2

  • Adeno Associated Virus Like Particles as a vaccine platform.
  • Broad coverage HPV vaccine without adjuvant, targeting the L2 minor capsid protein.
  • Prophylactic and therapeutic AAVLP-HER2/Neu vaccine.

back to speakers